Opop schreef op 18 aug 2019 om 10:17:
"Rinvoq carries a black box warning identifying safety concerns that include deep vein thrombosis (DVT) and pulmonary embolism (PE), and its sales could suffer if looming competitors such as filgotinib, an oral JAK-1 inhibitor from Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG), demonstrate an improved safety profile.
There were four adjudicated cases of PE in patients who received Rinvoq in the Phase III SELECT-BEYOND trial in 498 patients with moderate to severe RA. Only one adverse event of DVT or PE was reported with filgotinib in all 2,088 patents who received the compound in three Phase III FINCH studies for RA"
De FDA zal hier toch niet omheen kunnen; beter safety profile Filgotinib bij de onderzochte 2088 patiënten t.o.v. de 498 bij Upadacitinib.
Hoe zeker wil je het hebben.www.biocentury.com/bc-extra/company-n...
"Gilead gained rights to filgotinib for inflammatory diseases from Galapagos in December 2015, less than three months after AbbVie declined its option to the compound, instead choosing to develop its internally discovered upadacitinib."Zou AbbVie ooit spijt betuigen?